Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240019 · ClinicalTrials.gov registry record · NA
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
A NA study of Diabetic Nephropathy, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00240019 is a NA study of Diabetic Nephropathy that has completed, run by Stanford University. The registered enrollment target is 30 participants, below the 11,428-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00240019, a NA study of Diabetic Nephropathy, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.
Conditions Studied
Interventions
- DRUG Addition of furosemide 20 mg oral bid to baseline regimen
Study Locations (2)
California
- Kaiser Permanente of Northern California, Santa Clara and San Jose - Santa Clara
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240019
The ClinicalTrials.gov registry entry for NCT00240019 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 11,428-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Addition of furosemide 20 mg oral bid to baseline regimen is the first listed.
NCT00240019 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00240019 about?
NCT00240019 is a clinical study titled "Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.". The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibit...
What is the current status of trial NCT00240019?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2003-12. Estimated completion is 2006-04.
What conditions does trial NCT00240019 study?
This clinical trial studies the following conditions: Diabetic Nephropathy.
What interventions are being tested in trial NCT00240019?
The interventions under investigation include: Addition of furosemide 20 mg oral bid to baseline regimen (DRUG).
Who is sponsoring clinical trial NCT00240019?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00240019 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
COMPLETED · Phase 2
-
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
COMPLETED · Phase 2
-
Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.